Alpha Cancer Technologies
About Us
Our Products
Alpha Fetoprotein (AFP)
Immunotherapy Platform
Targeted Immuno-Oncology Platform
Pre-Clinical Studies
ACT-101 Pre-Clinical MG Studies
ACT-101 Pre-Clinical IBD Studies
ACT-901-3 Pre-Clinical IO Studies
News
Investors
Alpha Cancer Technologies
About Us
Our Products
Alpha Fetoprotein (AFP)
Immunotherapy Platform
Targeted Immuno-Oncology Platform
Pre-Clinical Studies
ACT-101 Pre-Clinical MG Studies
ACT-101 Pre-Clinical IBD Studies
ACT-901-3 Pre-Clinical IO Studies
News
Investors
CEO Dr. Igor Sherman Featured in CEOCFO Magazine
July 12, 2022
Recent Posts
CEO Dr. Igor Sherman Featured in CEOCFO Magazine
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, in Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Alpha Cancer Technologies Inc. Announces Acceptance of Abstract for Online Publication at the 2022 American Society of Clinical Oncology Annual Meeting
Alpha Cancer Technologies Inc. Presents New Data from ACT-903, an AFP-maytansine Conjugate, at 2021 European Society of Medical Oncology Annual Meeting
AFP-Maytansine Conjugate – a Novel Targeted Cancer Immunotherapy
